In Brief: Citi Pharmaceuticals Friatroy
This article was originally published in The Tan Sheet
Executive Summary
Citi Pharmaceuticals Friatroy: Herbal product is being distributed with claims for, among other things, tumor mass reduction, decrease in tumor markets, decrease in asthenia (weakness or loss of strength), reduction in pain and as a diuretic, FDA states in a Jan. 16 warning letter to the Miami-based firm. Citi published ads for conferences/seminars that state that "doctors will speak about Friatroy for the treatment of cancer and HIV/AIDS," FDA notes, making the product an unapproved drug for those diseases...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning